ArticleThe EPMA journal2020
A risk model of prenatal screening markers in first trimester for predicting hypertensive disorders of pregnancy.
Article in The EPMA journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Second trimester maternal serum D-dimer combined with alpha-fetoprotein and free β-subunit of human chorionic gonadotropin predict hypertensive disorders of pregnancy: a systematic review and retrospective case-control study.Journal of translational medicine · 2021Pooled it
- PAPPA's role in female reproduction.Reproduction (Cambridge, England) · 2025Review
- Evaluating an Early Risk Model for Uncomplicated Hypertension in Pregnancy Based on Nighttime Blood Pressure, Uric Acid, and Angiogenesis-Related Factors.International journal of molecular sciences · 2025Article
- The Association and diagnostic value between Maternal Serum Placental Markers and Placenta Previa.European journal of obstetrics & gynecology and reproductive biology: X · 2024Article
- Early Trimester Maternal Serum β-hCG and PAPP-A Levels as Predictor of Hypertensive disorders of Pregnancy.Journal of obstetrics and gynaecology of India · 2024Article
- Physiology of Pregnancy-Related Acute Kidney Injury.Comprehensive Physiology · 2023Article
- Maternal prenatal screening programs that predict trisomy 21, trisomy 18, and neural tube defects in offspring.PloS one · 2023Article
- Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18.Scientific reports · 2022Article
- Postpartum Assessment of the Correlation between Serum Hormone Levels of Estradiol, Progesterone, Prolactin and ß-HCG and Blood Pressure Measurements in Pre-Eclampsia Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Construction and predictive value of risk models of maternal serum alpha-fetoprotein variants and fetal open neural tube defects.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- External Quality Assessment of Maternal Serum Levels of Alpha-Fetoprotein, Free Beta-Human Chorionic Gonadotropin, and Unconjugated Estriol in Detecting Down Syndrome and Neural Tube Defects in the Second Trimester of 87 Maternal Serum Samples, Based on 105-139 Days.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- A Risk Model for Predicting Fetuses with Trisomy 21 Using Alpha-Fetoprotein Variants L2 Combined with Maternal Serum Biomarkers in Early Pregnancy.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- A risk model that combines MAP, PlGF, and PAPP-A in the first trimester of pregnancy to predict hypertensive disorders of pregnancy.Journal of human hypertension · 2022Article
- Article
- Predicting Hypertensive Disease in the First Trimester of Pregnancy: Risk Models and Analysis of Serum D-dimer Levels Combined with Plasma Pregnancy-Associated Protein A, FreeBioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to construct a risk model to assess the diagnostic value of predicting hypertensive disorders of pregnancy (HDPs) by screening a range of prenatal markers, including pregnancy-associated plasma protein A (PAPP-A), free beta-human chorionic gonadotropin (free β-hCG), and fetal nuchal translucency (NT).
methodWe analyzed 902 women, classified into four groups: healthy gravidas (
resultsLevels of PAPP-A and free β-hCG levels in the GH, PE, and SPE groups were significantly lower than those in the control group (
conclusionThe use of prenatal screening markers during early pregnancy can identify fetal aneuploidy and can also predict HDPs. The development of innovative screening strategies for gravidas and the targeted prevention of HDPs in high-risk gravidas are essential for perinatal care and early intervention, thus creating significant opportunities for predictive and preventive personalized medicine. In our study, we found that the combination of a series of prenatal screening markers in early pregnancy is better than a single marker; our data clearly demonstrate the diagnostic value of combining PAPP-A, free β-hCG, and NT for patients with SPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.